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Abstract
Purpose of Review The purpose of this review was to review
the imaging, particularly positron emission tomography
(PET), findings in neurorestoration studies in movement dis-
orders, with specific focus on neural transplantation in
Parkinson’s disease (PD) and Huntington’s disease (HD).
Recent Findings PET findings in PD transplantation studies
have shown that graft survival as reflected by increases in
dopaminergic PETmarkers does not necessarily correlate with
clinical improvement. PD patients with more denervated ven-
tral striatum and more imbalanced serotonin-to-dopamine ra-
tio in the grafted neurons tended to have worse outcome. In
HD transplantation studies, variable graft survival and clinical
responses may be related to host inflammatory/immune re-
sponses to the grafts.
Summary Information gleaned from imaging findings in pre-
vious neural transplantation studies has been used to refine
study protocol and patient selection in future trials. This in-
cludes identifying suitable candidates for transplantation
using imaging markers, employing multiple and/or novel
PET tracers to better assess graft functions and inflammatory
responses to grafts.
Keywords Neural transplantation . Emission tomography .
Parkinson’s . Huntington’s
Introduction
In the last few decades, a tremendous amount of effort has
been invested in finding a disease-modifying treatment for
various neurodegenerative disorders. Neurorestoration aims
to replace the lost or dysfunctional neurons and/or glial cells
in the diseased brain. This may be achieved through several
means, including (i) administration of neurotrophic factors to
promote neurogenesis or (ii) cell replacement therapy/neural
transplantation with neuroprogenitor cells [1].
Neural transplantation has been trialled in a number of
movement disorders where a predominant cell-type is prefer-
entially lost, such as substantia nigra dopaminergic neurons in
Parkinson’s disease (PD) and striatal medium-spiny projection
neurons in Huntington’s disease (HD), in an attempt to replace
the affected neurons. The outcomes of these studies are some-
what variable. Many human studies have not been able to
consistently reproduce the successes seen in initial pilot stud-
ies or animal studies.
Functional imaging, particularly positron emission tomog-
raphy (PET), gives us a unique opportunity to study in vivo
the survival and functional integration of implanted cellular
grafts. In this review, we will discuss how PET findings in
neurorestorative studies help us understand the outcome of
completed clinical trials, and how it can help refine and im-
prove restorative strategies for future studies. The review will
focus on neural transplantation studies in PD and HD, with
some discussions on restorative studies using neurotrophic
factors.
Neural Transplantation in Parkinson’s Disease
Research on intrastriatal transplantation of dopamine-rich hu-
man foetal ventral mesencephalic tissue for PD patients began
in the late 1980s [2–7] with these and ensuing open-label
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clinical trials reporting significant symptomatic improvement
and reduction in levodopa requirements in several cases
[8–34].
PET, utilised mainly in conjunction with dopaminergic
radioligand markers, has been a vital tool for objectively
assessing post-operative grafted cell function in vivo. In par-
ticular, 18F-DOPA, a fluorinated analogue of the dopamine
precursor L-DOPAwhich follows the same synthetic pathway
of decarboxylation by aromatic amino acid decarboxylase and
storage in presynaptic vesicles as 18F-labelled dopamine [35,
36], has enjoyed frequent usage for its ability to provide mea-
surements of dopamine synthesis and storage alterations in the
grafted striatum. A multitude of early open-label trials have
reported elevations of 18F-DOPA uptake in transplanted nuclei
to within “normal range” as early as 8 months post-transplant,
showing averaged increases of 40–120% at 12 months as
compared to pre-operative baseline levels. In some cases, the
improvements in PET uptake cases were sustained for up to
16 years with associated clinical benefit [8, 11, 13, 15, 16, 19,
25, 30–34, 37–39], demonstrating long-term survival and vi-
ability in the host environment. In accordance with this, acute
administration of methamphetamine or L-DOPA in
transplanted patients has been shown to cause significantly
greater reductions in 11C-raclopride binding as compared to
non-transplanted individuals [29, 37–41]. 11C-raclopride is a
weak reversible D2 receptor antagonist which is displaced
when in competition with extracellular dopamine (DA);
hence, drug-induced changes with respect to saline can be
interpreted as a surrogate marker of DA release. Normalised
11C-raclopride binding reductions have been observed from
the 5th to the 16th post-operative year [37–39], where even
in the worst cases, the percentage decreases were still signif-
icantly greater than in non-transplanted putamina [29, 41].
Moreover, changes in 11C-raclopride binding were negatively
related to changes in 18F-DOPA uptake [41]. Collectively,
these findings were taken to reflect a functional capability
for grafted neurons to release endogenous dopamine and to
at least partially restore post-synaptic D2 receptor occupancy.
The degree to which the grafted neurons express the dopa-
mine transporter (DAT), a transmembrane protein that facili-
tates reuptake of extracellular DA, has however been some-
what less consistent across studies. Despite a significant 18F-
DOPA increase, Cochen et al. found in a group of six patients
no change in striatal DAT binding using 76Br-FE-CBT PET
[42]. In contrast, others have demonstrated large increases in
DAT density detectable by 5–6 months after transplant, based
on 11C-nomifensine binding asymmetry between grafted and
non-grafted striata [14] and pre-post-operative changes in 123I-
IPT binding [43]. Continual rises in 123I-IPT and 123I-FP-CIT
binding have been observed in the long term but not necessar-
ily uniformly across target regions, with one patient sustaining
normal levels 14 years after transplant in the clinically least
affected striatum but reversal to baseline levels following an
initial increase over the first 3 years in the more affected stri-
atum [37, 43], possibly reflecting variability in tissue quality
or an effect of lateralised disease severity [43]. Interestingly,
changes in 76Br-FE-CBT binding and 18F-DOPA uptake be-
tween scanning sessions were not correlated [42], suggesting
that the ability for grafted neurons to synthesise DA is not
necessarily related with their capability for re-innervating the
host striatum. Despite this, graft-related increases in DATwere
accompanied by improvements in general motor severity and
vice versa across time points in several studies [14, 42, 43],
suggesting that DA terminal integrity is an important factor
which may contribute to clinical outcome.
Studies employing non-dopaminergic imaging techniques
have provided further supplementary information on graft sur-
vival and function. Using proton magnetic resonance spec-
troscopy, Ross et al. demonstrated that the concentration of
N-acetylaspartate around the putaminal graft sites, a metabo-
lite marker of neuronal viability and maturity which is not
present in foetal neurons, was only marginally shy of pre-
operative levels approximately 1 year after surgery, with the
lowest detected concentrations still significantly higher than in
foetal tissue assayed in vitro [44]. Functional magnetic reso-
nance imaging has revealed arm movement-related activation
within these graft sites 2–3 years after surgery [45], indicating
sustained functional integration of the foreign tissue following
a plateau in graft-related increases of dopamine synthesis.
Indeed, while increases in 18F-DOPA uptake predominantly
occurred within the first 18 months with negligible change
beyond this point [8, 11, 22, 46], H2
15O PET demonstrated
that the restoration of downstream cortical motor is relatively
delayed, illustrating significantly increased cerebral blood
flow during left-handed motor joystick movements in the ros-
tral supplementary motor area and right dorsolateral prefrontal
cortex at 18 months post-graft but not at 6.5 months [30].
More recently, single unit recordings in a patient transplanted
10 years prior have demonstrated long-term electrophysiolog-
ical changes in neurons of the globus pallidus interna (GPi).
While oscillatory activity remained abnormal, compared to
non-transplanted individuals in the “OFF-state”, resting dis-
charge rates were significantly reduced and voluntary hand
movements were associated with marked inhibition of neuro-
nal firing by ~ 63% relative to baseline. No alterations were
observed in the external palladium; hence, beneficial modula-
tion of GPi outflow and subsequent thalamo-cortical activity
most likely originated from increased dopaminergic effect on
D1-type striatal GABAergic medium spiny neurons within the
direct basal ganglia pathway [47].
Despite showing promise, progress in foetal cell therapy
was hindered when around the turn of the century, two large
NIH-funded double-blind randomised controlled designs in-
cluding sham controls produced no or marginal symptomatic
improvement in patients receiving transplantation [46, 48].
Putaminal dopamine synthesis increased by only 20–40%
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[46, 48] and although 18F-DOPA measures were comparable
between older (> 60 years) and younger (< 60 years) patients,
only in the younger group did changes in putaminal 18F-
DOPA uptake post-surgery correlate with changes in
UPDRS [48, 49]. It is worth noting that the sham-surgery
groups continued to deteriorate both in terms of motor severity
and 18F-DOPA uptake [46, 48], which opposes suggestions of
placebo effects in prior open-label studies and raises further
questions regarding the impact of differing trial methodology
on patient outcome. Nonetheless, these data raise the possibil-
ity of a critical threshold of graft survival below which symp-
tomatic improvement may be negligible and that the host age
could to some degree modulate the extent to which or length
of time taken for the implants to become functional [50].
Disease severity may also play a role in determining ther-
apeutic effect. Two studies retrospectively analysing the ex-
tent of denervation in patients prior to transplant have shown
that individuals displaying 18F-DOPA reductions extending to
the ventral striatum were less likely to derive clinical benefit
[22, 41]. In the substantia nigra, 18F-DOPA continues to de-
crease post-surgery, indicating that striatal grafts despite
boosting striatal DA synthesis do not prevent the continual
degeneration of native nigrostriatal neurons [41]. These find-
ings highlight the importance of patient selection and under-
line the utility of 18F-DOPA as a potential screening tool for
objectively determining disease progression. It would seem
that foetal cell therapy may not be appropriate for second-
line use, after patients in advanced disease stages exhibit in-
adequate response to dopaminergic drugs.
In addition to the inadequate clinical improvement in
blinded trials, were reports of patients exhibiting abnormal
involuntary movements in the “OFF-state”, emerging as early
as 5 months after grafting which sometimes necessitated ad-
ditional surgical intervention [21, 46, 48, 51, 52]. These
movements, later termed graft-induced dyskinesia (GID)
[53], were in fact noted in some patients from open label trials
[54–56] but for the most part overlooked, perhaps due to the
lack of sensitive and specific assessment tools for their detec-
tion in milder cases [53]. Initially, it was suggested that con-
tinued fibre outgrowth from transplantation sites could be re-
sponsible for an eventual excess of dopamine [48]. Indeed,
surplus DA could cause over-inhibition of GPi outflow in a
topographically unspecific manner, as revealed by single unit
recordings, as well as increases in irregular discharge patterns
akin to the electrophysiological properties observed for GPi
neurons in non-transplanted patients during the “ON-state”
[47]. However, the degree of reinnervation as assessed using
18F-DOPA does not correlate with GID severity [46, 51, 52]
and is comparable between patients with andwithout GID [46,
52]. The possibility of excessive dopamine release has been
addressed using 11C-raclopride following intravenous admin-
istration of methamphetamine. In grafted patients who had
developed GIDs, Piccini et al. found a 9.55% decrease in
putaminal binding potential following drug-induced DA re-
lease relative to following saline, as compared to 25.2% in
healthy individuals and 6.84% in non-grafted PD patients
[41, 57]. There was no association between the degree of
drug-induced 11C-raclopride displacement and GID severity
[41]. Moreover, in one case study of a patient reportedly un-
affected by GID, 11C-raclopride binding indicated a normal-
isation of dopamine release (26.6% decrease compared to sa-
line) in the transplanted putamen [29]. Taken together, these
imaging data demonstrate that GID is unlikely to be associated
with excessive dopamine synthesis or release from presynap-
tic terminals of grafted DA neurons.
The site of cell deposition and patchy or uneven reinnerva-
tion has also been suggested as possible factors for the emer-
gence of GID [46, 48, 52, 53, 58]. Ma et al. employing para-
metric and sub-regional analysis of 18F-DOPA uptake in
transplanted patients found that individuals who developed
GID appeared to have significantly greater post-operative
18F-DOPA increases in the relatively preserved ventral puta-
men as compared to patients who attained good clinical ben-
efit but did not develop GID [21], supporting earlier sugges-
tions that putaminal grafting should be weighted towards the
more denervated dorsal aspect [48]. Another 18F-DOPA study
indicated that patients who were deemed to have the best
global ordered outcome score, a composite metric pertaining
to the relative significance of clinical benefit versus side ef-
fects, exhibited preservation of ventral striatal 18F-DOPA up-
take. In contrast, those with low global ordered outcome score
showed significant denervation of the ventral striatum either
prior to or within the first 2 years of surgery [41]. This may
indicate that the balance between clinical benefit and GID
may be in part sensitive to the pre-operative ventral striatal
dopaminergic state and that cell deposition strategies should
entail case-by-case evaluations to promote more homogenous
reinnervation.
More recently, attention has shifted towards grafted cell
composition with particular focus on the subsequent growth
of serotonergic neurons [27], which are known to be capable
of converting L-DOPA and storing and releasing dopamine in
an activity-dependent manner. Critically, the absence of nec-
essary D2-autoreceptor-mediated feedback and dopamine
transporters on serotonergic terminals ultimately leads to dys-
regulated release and excessive swings in extracellular DA
levels that could potentially cause involuntary and uncontrol-
lable movement [59–62]. Politis et al. tested this hypothesis
in vivo in three transplant case studies of patients who had
derived favourable long-termmotor benefits with concomitant
normalisation of dopamine synthesis (18F-DOPA) and release
(11C-raclopride) but who also developed severe GIDs [37, 39].
Using 11C-DASB, which binds selectively to the serotonin
transporter (SERT), a membrane protein that facilitates the
reuptake of serotonin back into the presynaptic terminal, pa-
tients were found to exhibit increases in putaminal SERT
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expression by 46–172 and 106–285% of the mean binding
values calculated for healthy controls and non-transplanted
advanced PD patients respectively (Fig. 1) [37, 39]. In all three
cases, administration of the 5-HT1A agonist (buspirone),
which dampens serotonergic neurotransmission by
autoreceptor stimulation, substantially attenuated GID severi-
ty by ~ 75% while UPDRS-based motor severity measures
remained unchanged. While these findings support serotoner-
gic involvement, they do not sufficiently explain why the
levels of serotonergic hyperinnervation differed between two
patients (46 vs. 77%) who reportedly displayed comparable
GID severity [37, 39]. In theory, dopamine transmission
should not entail serotonergic involvement if the density of
dopaminergic neurons in the local environment is substantial.
Indeed, when considering the ratio of 11C-DASB binding to
18F-DOPA uptake, both patients exhibited similar elevations
of 140 and 146% as compared to ratios in healthy individuals
[37, 39].
Although data are limited and do not involve grafted indi-
viduals who did not develop GID, they appear to suggest that
it is the relative density of serotonergic to dopaminergic inner-
vation that dictates the degree of dopamine mishandling rather
than serotonergic hyperinnervation as a sole causal factor.
Clearly, improvements in cell sorting methodologies would
be needed to reduce the risk of side effects, but so too would
more comprehensive patient selection. For instance, in one
open-label cohort, a near significant negative correlation was
found between pre-operative putaminal 18F-DOPA and GID
whereas no relationships were identified with post-operative
18F-DOPA [51]. Although this was not replicated in a blinded
cohort [52], it is worth considering the exclusion of advanced
patients, in whom severe dopaminergic denervation has al-
ready occurred and who may be predisposed to attaining del-
eteriously imbalanced post-operative 5-HT-to-DA neuronal
ratios.
Contrary to this, 11C-DASB binding in the raphe nuclei and
several extrastriatal regions receiving dense serotonergic in-
nervation including the amygdala, thalamus, insula, cingulate,
and prefrontal cortices continues to decrease following sur-
gery [38]. Thus, while maintaining a healthy striatal 5-HT-
to-DA balance may be necessary to prevent movement-
related side effects, without additional targeted grafting of 5-
HT neuroblasts, foetal cell therapy may not be enough to
alleviate PD symptomatology where serotonin is known to
play a role, such as tremor amplitude and constancy [63] and
non-motor complications including depression [64–66] and
fatigue [67], all of which may have a profound effect on over-
all quality of life.
Collectively, the imaging data obtained to date has provid-
ed in vivo evidence that foetal cell transplants can survive,
produce, and release dopamine in the host brain and function-
ally integrate to an extent which can result in significant long-
term motor improvements. Side effects such as graft-induced
dyskinesias may have emerged in some cases as a conse-
quence of patchy innervation, inappropriate targeting, impure
cell suspensions, and/or the selection of advanced patients in
whom pre-operative dopaminergic innervation levels were se-
verely compromised. In vivo imaging has been and will con-
tinue to be paramount in monitoring the progress of patients
receiving cell therapy and for providing an objective tool for
Fig. 1 Role of striatal serotonergic hyperinnervation in graft-induced
dyskinesia in Parkinson’s disease. 11C-DASB PET summation images
of two Parkinson’s disease (PD) patients, co-registered on their
individual MRI brain, showing their serotonin transporter (SERT)
binding. a A 65-year-old male PD patient with 16 years disease
duration and motor fluctuations, exhibiting reduced striatal 11C-DASB
binding. b A 65-year-old male PD patient who received bilateral foetal
striatal transplantation 16 years ago, experiencing graft-induced
dyskinesia despite not taking any dopaminergic medications. His 11C-
DASB PET showed significantly increased SERT binding in the
striatum. Modified from Politis et al. [39]
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screening patients with high likelihood of deriving clinical
benefit. The use of magnetic resonance imaging has so far
been limited but would offer significant insight into the be-
haviour of the grafted cells post-surgery and their ability to
form functional connections within the effective motor net-
work. Other PET ligands such as those that target the periph-
eral benzodiazepine receptor or TSPO (e.g. 11C-(R)-PK11195
and 11C-PBR28) found on activated microglia should be con-
sidered in future trials for evaluating the degree of immuno-
logical reactivity at and around the transplant sites which,
based on histopathological and 18F-DOPA PETexaminations,
has been proposed by some as a possible hindrance to long-
term clinical efficacy upon premature immunosuppressive
withdrawal [41, 46, 48, 68–70]. Moreover, given reports of
grafted neurons displaying Lewy pathology at post-mortem
[68, 69, 71•, 72, 73••], monitoring α-synuclein and its aggre-
gation over time is another important consideration. Despite
some promising first reports on 11C-BF-227 [74, 75] and
125I-SIL23 [76], synthesis of PET radioligands with high
affinity and selectivity for α-synuclein has presented as a
major challenge [77•], though recent work into their de-
velopment and the identification of new compounds e.g.
[78] give hope that this could soon be available for use in
future clinical trials.
Neurotrophic Factors in Parkinson’s Disease
A handful of clinical trials have been performed to investigate
the efficacy of neurotrophic factors in PD. Glial cell line-
derived neurotrophic factor (GDNF) is a dopaminergic neuro-
trophic factor. Initial open-labelled pilot study of five PD pa-
tients showed both clinical and 18F-DOPA PET improvement
following intraputaminal delivery of recombinant human
GDNF [79]. However, a subsequent multi-centre double-blind
randomised-controlled study showed no clinical benefit of
GDNF treatment, despite an increase in striatal 8F-DOPA
PET uptake [80]. Limited diffusion of GDNF in the putamen
and placebo effect were among the factors cited for the differ-
ences in outcome between the open-labelled and double-blind
studies. One patient from the initial pilot study demonstrated
persistent clinical and 18F-DOPA PET improvement despite
cessation of GDNF infusion for 3 years [81], suggesting that
heterogeneity in patient responses, similar to that seen in PD
transplantation studies, may also play a part in the negative
outcome in the multi-centre study.
Neurturin is a naturally occurring structural and functional
analogue of GDNF [82]. Randomised controlled studies
injecting adeno-associated virus type 2 vector expressing
neurturin into the putamen [83], and into both putamen and
substantia nigra [84], of PD patients also failed to reach their
primary end points. No functional imaging was undertaken in
both of these studies.
Neural Transplantation in Huntington’s Disease
The pathological hallmark of HD is progressive and severe
atrophy of the striatum. Medium spiny projection neurons of
the striatum, which express dopamine receptors and corre-
spond to 90–95% of the striatal neuronal population, are pref-
erentially lost in HD [85]. As the disease progresses, cerebral
cortex, subcortical white matter, and other brainstem and basal
ganglia structures are also affected.
11C-raclopride binding to striatal neurons of HD patients
provides a marker of disease progression and correlates cross-
sectionally with disability scores on the Unified Huntington’s
Disease Rating Scale (UHDRS) [86]. In early-mid stage HD,
the striatal D2 receptor binding, as measured by
11C-raclopride
PET, fell by 5–6.3% per annum [87, 88]. PET studies on
rodent models of HD which have received implantation of
foetal striatal cells have shown improvement in striatal 11C-
raclopride binding, due to the expression of dopamine D2
receptors by the surviving grafts. This improvement correlated
with graft survival, particularly with the striatal-like tissues
within the grafts (the “P zones”), and functional improvement
[89]. It is the recommended functional imaging modality to
assess graft survival for the Core Assessment Program for
Intracerebral Transplantations in Huntington’s Disease
(CAPIT-HD) assessment battery [90].
18F-fluorodeoxyglucose (18F-FDG) PET, which measures
cerebral glucose metabolism, has also been used in a number
of HD transplantation studies to assess graft survival.
However, 18F-FDG uptake mainly reflects cellular metabo-
lism and synaptic activity, which may be increased by a glial
reaction to grafting and hence does not specifically indicate
striatal graft survival. 18F-FDG does have an advantage over
11C-raclopride in that neuroleptics, which are frequently pre-
scribed for HD patients for their chorea or psychosis, can
interfere with D2 binding [91], but they do not affect cerebral
glucose metabolism.
Following the initial successes of open-labelled PD trans-
plantation studies as discussed in previous section, several HD
neural transplantation studies were carried out, where foetal
striatal allografts derived from either lateral ganglionic or
whole ganglionic eminences were implanted into host striata.
In one of the earlier UK pilot studies which included two HD
subjects who received foetal striatal transplantation, one had
sustained clinical improvement over 5 years which was ac-
companied by corresponding improvement in the striatal
11C-raclopride binding, indicating graft survival and function-
al integration. The other implanted patients did not improve
and the 11C-raclopride continued to decline at a rate commen-
surate with non-implanted HD controls [92].
A French study based in Creteil showed clinical and 18F-
FDG PET stabilisation/improvement for up to 4 years in three
out of five patients transplanted with foetal striatal allografts
derived from whole ganglionic eminence [93, 94]. In these
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three patients, clinical improvement was associated with an
improvement in striatal glucose metabolic rate and a reduction
in cortical hypometabolism, suggesting a partial restoration of
the cortico-striatal loop function [95]. However, all of them
gradually deteriorated after 4 years. The other two patients
showed no clinical or PET improvement after transplantation.
In a US study, seven HD patients who received foetal
striatal transplantation were assessed with 11C-SCH23390,
11C-raclopride, and 18F-FDG PET to measure striatal D1 and
D2 binding and regional cerebral glucose metabolism respec-
tively [96, 97]. There was no clinical or PET improvement in
all seven patients, despite post-mortem evidence of graft sur-
vival with striatal tissue and extension of host-derived dopa-
minergic fibres into the grafts in one patient who died of
cardiac disease 18 months post-transplantation [98]. There
was also no evidence of graft rejection, and the grafts were
not affected by HD pathology. A follow-up study involving
post-mortem report of three more patients showed that there
was evidence of graft survival and differentiation into medium
spiny neurons in two of the patients [99]. The medium spiny
neurons also received glutamatergic projection from cortical
neurons. However, the graft survival was attenuated over long
term and there was evidence of neuronal degeneration partic-
ularly involvingmedium spiny neurons. Microglial inflamma-
tory changes were also seen in the grafts which appeared to
target the neuronal components of the grafts. These findings
suggest selective vulnerability of medium spiny neurons to
cellular stressors, such as excitotoxicity and microglial activa-
tion, rather than the involvement of grafted neurons by prima-
ry HD pathology, as no nuclear inclusion or huntingtin protein
was detected in these grafts [100].
In a German study, ten HD patients received foetal striatal
transplantation [101]. Half of them developed HLA-
antibodies of class I and II post-transplantation. Some of them
developed the antibodies while taking immunosuppressants,
while others developed after cessation of immunosuppression.
Only one transplanted patient demonstrated transient clinical
improvement for 24 months post-transplantation, and this was
despite the presence of HLA-antibodies post-transplantation.
None of the patients, however, demonstrated an increase in
cerebral or striatal 18F-FDG PET uptake.
In a more recently published Italian study, ten HD patients
received foetal striatal transplantation. Compared with non-
transplanted HD controls, the transplanted patients demon-
strated a slower slope of decline in their motor and cognitive
assessments [102]. There was also increased striatal 18F-FDG
PET uptake in the transplanted group up to 4 years. Three of
the ten patients also received [123I]-iodobenzamide SPECT to
image D2 status, and there was an increase in striatal D2 bind-
ing at 12 months post-operatively compared to baseline.
In another UK study, no clinical or 11C-raclopride PET
improvement was seen in all five HD subjects implanted with
foetal striatal grafts [103]. One of the transplanted subjects
also received 11C-(R)-PK11195 PET pre- and post-
implantation to assess microglial activation. In this subject,
the level of microglial activation in the striatum was higher
than a group of non-grafted HD controls 1 year post-implan-
tation. The persistent microglial activation around the graft
was detected by post-mortem in this particular patient 12 years
post-transplant, indicating a possible role of microglial activa-
tion in the survival of implanted neural tissue (manuscript
submitted).
Overall, the outcome of HD neural transplantation studies
was heterogeneous. For the few transplanted subjects who
demonstrated clinical improvement, there was generally a cor-
responding improvement in their PETmarkers of graft surviv-
al or activity, apart from one subject in the German study who
showed transient clinical improvement [101]. Conversely,
none of the patients who did not improve clinically displayed
an improvement in their PET parameters. This suggests that
despite post-mortem evidence of graft survival in most of the
patients examined (incidentally, none of those who underwent
post-mortem examination experienced improvement after
transplantation), insufficient graft survival may partially ex-
plain the lack of PET and clinical improvement. There are a
number of factors that are thought to affect graft survival,
including microglial activation, alloimmunisation, lack of
graft vascularisation, and loss of trophic support due to atro-
phic astrocytes around the graft [104, 105•]. However, as PD
transplantation studies tell us, evidence of significant graft
survival might not necessarily lead to clinical improvement.
It may require a more complete integration of graft into the
host circuitry and normalisation of neurotransmitters release
in the host environment.
Conclusion
Imaging and pathological findings have informed us that graft
survival does not necessarily translate to clinical improvement
in neural transplantation studies. The heterogeneity in patient
responses may partially contribute to the differences in out-
come between open-labelled and subsequent double-blind
studies in PD. PET findings can help to identify and select
patients who are more likely to do well in neural transplanta-
tion studies. They also highlight the importance of restoring
normal balance of neurotransmitters in the host brain. Clinical
improvement in HD transplantation studies is generally less
impressive than that seen in PD open-labelled studies.
Variable graft survival and host inflammatory response, as
revealed by PET, could play an important part.
The lessons learned from imaging findings in previous
neural transplantation studies are being used to refine protocol
and patient selection for future studies (e.g. TRANSEURO for
PD [103] and MIG-HD for HD [106]). The shift in interest
from foetal progenitor cells to stem cells has also rejuvenated
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the neural transplantation field [107]. Functional imaging will
continue to play an important role in assessing the outcome of
these trials.
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